Potential Side Effects of Levitra

Levitra > levitra drug


Sudden death and QT prolongation have occurred in patients receiving nilotinib therapy.

  • Levitra is approved for the treatment of erectile dysfunction in men over 18.
  • It is not recommended for use in women or children.
  • The medication is usually taken orally, in tablet form.
  • Levitra's effectiveness relies on sexual stimulation to initiate an erection.
  • Adverse effects are typically mild but can include dizziness and upset stomach.
  • Consult your healthcare provider if you experience prolonged or painful erections.
  • Levitra should be used cautiously in men with liver or kidney disease.
  • Always disclose your complete medical history to ensure safe use.

Also, nilotinib is a moderate CYP3A4 inhibitor and vardenafil is a primary CYP3A4 substrate; administering these drugs together may result in increased vardenafil concentrations.

Precaution Rationale
Cardiovascular health assessment Risk of cardiac events
Alcohol consumption Can impair effectiveness or increase side effects
Use with caution in elderly Altered pharmacodynamics
Underlying vision issues Rare visual side effects

Do not use vardenafil orally disintegrating tablets with nilotinib due to increased vardenafil exposure.

Get case insights

Mobocertinib: (Major) Concomitant use of mobocertinib and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Moxifloxacin: (Major) Concomitant use of vardenafil and moxifloxacin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Nefazodone: (Major) Do not use vardenafil orally disintegrating tablets with nefazodone due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; nefazodone is a strong CYP3A4 inhibitor. Nelfinavir: (Major) Do not use vardenafil orally disintegrating tablets with nelfinavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets.

Can vardenafil and tadalafil be taken together?

Vardenafil is primarily metabolized by CYP3A4/5; nelfinavir is a strong CYP3A4 inhibitor. Netupitant, Fosnetupitant; Palonosetron: (Major) Do not use vardenafil orally disintegrating tablets with netupitant due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; netupitant is a moderate CYP3A4 inhibitor. Nicardipine: (Moderate) Vardenafil is metabolized by hepatic cytochrome P450 3A4 and to a lesser extent CYP2C9. Inhibitors of CYP3A4, such as nicardipine, can reduce levitra shipping vardenafil clearance. If use of nilotinib and vardenafil oral tablets is required, do not exceed a single vardenafil oral tablet dose of 5 mg per 24-hour period.

Product Dosage Quantity + Bonus Price
Levitra Original20mg22 + 2 Pills138.55€ 131.95€
Levitra Generic40mg90 + 6 Pills234.73€ 223.55€
Levitra Generic60mg360 + 10 Pills906.69€ 863.51€
Levitra Soft Tabs20mg360 + 20 Pills682.21€ 649.72€
Levitra Generic60mg20 Pills81.30€ 77.43€
Levitra Generic10mg10 Pills28.93€ 27.55€
Levitra Generic40mg120 + 8 Pills302.37€ 287.97€
Levitra Original20mg120 + 8 Pills528.19€ 503.04€
Levitra Soft Tabs20mg270 + 10 Pills521.78€ 496.93€
Levitra Soft Tabs20mg20 Pills74.68€ 71.12€
Levitra Professional20mg270 + 6 Pills738.98€ 703.79€
Levitra Original20mg76 + 4 Pills344.39€ 327.99€
Levitra Original20mg64 + 4 Pills298.45€ 284.24€
Levitra Original20mg48 + 4 Pills235.14€ 223.94€

Nirmatrelvir; Ritonavir: (Major) Consider withholding vardenafil during receipt of ritonavir-boosted nirmatrelvir.

Earn extra money

Increased systemic exposure to vardenafil may result in an increase in vardenafil-induced adverse effects. Nifedipine: (Moderate) Nifedipine can have additive hypotensive effects when administered with phosphodiesterase inhibitors (PDE 5 inhibitors). The patient should be monitored carefully and the dosage should be adjusted based on clinical response. For example, in patients whose hypertension was controlled with nifedipine, vardenafil produced mean additional supine systolic/diastolic blood pressure reductions of 3 to 4 mmHg (age group 65 to 69 years) and 5 to 6 mmHg (age group 70 to 80 years) compared to placebo. Nilotinib: (Major) Avoid the concomitant use of nilotinib with other agents known to prolong the QT interval, such as vardenafil. Coadministration may increase vardenafil exposure bayer levitra 20mg resulting in increased toxicity. Nitrates: (Contraindicated) Coadministration of phosphodiesterase inhibitors with organic nitrates or nitrites in any dosage formulation is contraindicated. Nitroglycerin: (Contraindicated) Coadministration of phosphodiesterase inhibitors with organic nitrates or nitrites in any dosage formulation is contraindicated. Nitroprusside: (Contraindicated) Concomitant use of nitroprusside and vardenafil is contraindicated due to the risk of additive hypotension. A suitable time interval after vardenafil dosing for the safe administration of nitrates has not been determined. In addition, vardenafil may potentiate the nitric oxide-mediated platelet anti-aggregatory effect of nitroprusside.

Aspect Levitra (Vardenafil) Sildenafil (Viagra) Tadalafil (Cialis)
Onset of action 25-30 minutes 30-60 minutes 30-60 minutes
Duration Up to 4-5 hours Up to 4 hours Up to 36 hours
Food interactions Less affected by food Delayed if taken after heavy meals Less affected by food
Side effect profile Similar to others, with possible visual disturbances Similar, with some headache Longer-lasting effect

Ofloxacin: (Moderate) Concomitant use of ofloxacin and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Olanzapine: (Moderate) Concomitant use of vardenafil and olanzapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Olanzapine; Fluoxetine: (Moderate) Concomitant use of vardenafil and fluoxetine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Warnings of Levitra and Viagra

(Major) Do not use vardenafil orally disintegrating tablets with ritonavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; ritonavir is a strong CYP3A4 inhibitor. Coadministration of ritonavir with vardenafil resulted in a 49-fold increase in levitra 5mg online vardenafil AUC and a 13-fold increase in vardenafil Cmax. Concomitant use may increase the risk of vardenafil-related adverse effects, such as prolonged erection or QT prolongation. Lorcaserin: (Moderate) Lorcaserin is a serotonin 2C receptor agonist, and priapism is a potential effect of 5-HT2C receptor agonism.

Who Should Not Take Viagra™

Because there is little experience with the combination of lorcaserin and medications indicated for erectile dysfunction (e.g., phosphodiesterase inhibitors), combined use should be approached with caution. Macimorelin: (Major) Concomitant use of vardenafil and macimorelin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Maprotiline: (Moderate) Concomitant use of vardenafil and maprotiline may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Mefloquine: (Moderate) Concomitant use of vardenafil and mefloquine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Methadone: (Major) Concomitant use of vardenafil and methadone increases the risk of QT/QTc prolongation and torsade de pointes (TdP).

How to Use Viagra™

Metronidazole: (Moderate) Concomitant use of metronidazole and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Midostaurin: (Major) Concomitant use of vardenafil and midostaurin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Mifepristone: (Major) Do not use vardenafil orally disintegrating tablets with mifepristone due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A and mifepristone is a strong CYP3A inhibitor. Mirtazapine: (Moderate) Concomitant use of vardenafil and mirtazapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. (Moderate) Concomitant use of vardenafil and olanzapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

  • Levitra's approval has expanded options for men seeking ED treatment.
  • It is one of several PDE5 inhibitors designed for erectile enhancement.
  • Men should consider potential side effects and interactions before use.
  • Levitra can be taken on an as-needed basis, not necessarily daily.
  • Proper diagnosis of ED involves a thorough medical examination.
  • Persistent ED can be a sign of underlying health issues needing attention.
  • Levitra’s pharmacokinetics allow for flexibility in planning for intimacy.
  • Always follow prescribed instructions to maximize safety and effectiveness.

Olanzapine; Samidorphan: (Moderate) Concomitant use of vardenafil and olanzapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Ondansetron: (Major) Concomitant use of ondansetron and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Osilodrostat: (Moderate) Concomitant use of vardenafil and osilodrostat may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Osimertinib: (Major) Concomitant use of vardenafil and osimertinib increases the risk of QT/QTc prolongation and torsade de pointes (TdP).

  • Levitra is available by prescription only and should be used under medical supervision.
  • It is important to follow the prescribed dosage for safety and effectiveness.
  • Levitra does not cause an instant erection; sexual stimulation is required.
  • Alcohol consumption can reduce Levitra's effectiveness and increase side effects.
  • Patients with heart problems should consult their doctor before taking Levitra.
  • Levitra was approved by the FDA for the treatment of erectile dysfunction in 2003.
  • In rare cases, Levitra may cause side effects like sudden vision loss.
  • Taking Levitra with certain medications can cause dangerous drops in blood pressure.

Oxaliplatin: (Major) Concomitant use of vardenafil and oxaliplatin increases the risk of QT/QTc prolongation and torsade de pointes (TdP).

Overdose/Missed Dose

Vardenafil is primarily metabolized by CYP3A; lenacapavir is a moderate CYP3A inhibitor. Lenvatinib: (Major) Concomitant use of vardenafil and lenvatinib increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Letermovir: (Major) Do not use vardenafil orally disintegrating tablets with letermovir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; letermovir is a moderate CYP3A4 inhibitor. Leuprolide: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., leuprolide) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Other Medical Problems

Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monit oring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Leuprolide; Norethindrone: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., leuprolide) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Levofloxacin: (Moderate) Concomitant use of levofloxacin and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Levoketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and vardenafil due to an increased risk for QT/QTc prolongation and torsade de pointes (TdP). Lithium: (Moderate) Concomitant use of vardenafil and lithium may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Is 20 mg Levitra equal to 100 mg Viagra?

Lonafarnib: (Major) Do not use vardenafil orally disintegrating tablets with lonafarnib due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; lonafarnib is a strong CYP3A4 inhibitor. Loperamide: (Moderate) Concomitant use of vardenafil and loperamide may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Loperamide; Simethicone: (Moderate) Concomitant use of vardenafil and loperamide may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Lopinavir; Ritonavir: (Major) Concomitant use of vardenafil and lopinavir increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Ozanimod: (Major) In general, do not initiate ozanimod in patients taking vardenafil due to the risk of additive bradycardia, QT prolongation, and torsade de pointes (TdP). If treatment initiation is considered, seek advice from a cardiologist. Ozanimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays.

Step Description
PDE5 inhibition Blocks enzyme PDE5, increasing cGMP levels
Increased cGMP Causes smooth muscle relaxation in corpora cavernosa
Erection initiation Blood flow into the penis increases, facilitating an erection

Ozanimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia.